among FSWs derived from independent data sources, was more consistent with observed HIV trends, and if these trends could have occurred without post-Avahan increases in CCU (two null hypotheses were assumed—one being more (H0b) and less conservative (H0a)). The most likely CCU hypothesis was used to predict the intervention impact on HIV prevalence/incidence and HIV infections prevented.

**Results** Using the most likely CCU hypothesis for each district (H1), results so far suggest that the increase in condom use post-Avahan may have resulted in between 21 and 45% of new HIV infections being averted among FSWs in Mysore, Bellgaum and Bellary respectively from 2004 to 2007. Similar results were obtained for clients but the absolute number averted was 2-8 fold more. Model projections (Abstract S7.3) suggest that this has resulted in the large decrease in HIV prevalence observed in these districts, and that this would not have occurred in the absence of Avahan. The syphilis treatment component alone prevented <9 and 13% of new HIV infections over 1 and 10 years. Impact projections for the general population and additional districts will be presented.

**Conclusions** These Bayesian modelling results, combined with observed HIV prevalence trends and evidence of successful implementation and scale-up of Avahan, provides plausible evidence that Avahan has reduced HIV transmission to a large extent among high-risk groups.

---

**S7.4 COST-EFFECTIVENESS OF TARGETED HIV PREVENTIONS FOR FEMALE SEX WORKERS: AN ECONOMIC EVALUATION OF THE AVAHAN PROGRAMME IN SOUTHERN INDIA**

1. S Chandrashekhar, 1 A Vassall, 1,2 L Guinness, 1,4 M Pickles, 2 B Reddy, 2 G Shetty, 4 M C Bolly, 2 K Lowndes, 2,3 M Alary, 1 P Vickerman. *London School of Hygiene and Tropical Medicine, London, UK; 2St Johns Research Institute, India; 3Australian Centre for Economics Research in Health, Australian National University; 4Imperial College, London, UK.*

**Objective(s)** The aim of the presentation paper is to assess the cost-effectiveness of HIV prevention interventions for female sex workers in India, in the context of large-scale programme effort, the Avahan Programme.

**Design/methods** We estimate cost-effectiveness using comprehensive measurements of cost; and, impact estimates based on dynamical transmission models of HIV and STI transmission that are fitted to observed prevalence trends. Our primary outcome measure is incremental costs per DALY averted (ICER) for the HIV prevention programme compared to a “do-nothing” base case.

**Results** In 2007, the implementing NGO cost per person reached at least once in a year ranges from US$47 to US$154. When all costs are taken into account (including expertise enhancement, management and contracting costs), the cost per person reached increases to US$112 to US$ 215, depending on location and year. Median incremental costs per infection averted range from US$ 876 (370, 3040) to US$2574 (1344, 7132). Median incremental costs per DALY averted range from US$49 (20.171) in to US$ 143 (74, 385). These costs per DALY may increase as results from other states are included.

**Conclusions** This study presents robust evidence that demonstrates that HIV prevention interventions targeted at high risk vulnerable groups can achieve substantial reductions in HIV infections at an acceptable cost in a concentrated epidemic setting. Moreover, we demonstrate cost-effectiveness in the context of a programme that is delivering HIV prevention at scale. However, the achievement of cost-effectiveness varies by setting. Our findings suggest that those responsible for HIV programmes should therefore consider funding targeted HIV prevention programmes at high risk groups in India and beyond, but should take into account setting specific drivers of the HIV epidemic. 

---

**Symposium 8: The global public health challenge of untreated multidrug-resistant Neisseria gonorrhoeae “superbug” (MDR-GC)**

**S8.1 LESSONS LEARNT FROM GLOBAL HIV DRUG RESISTANCE INITIATIVE: IMPLICATIONS FOR MDR-GC**

D Sutherland. *Global Public Health, Canada*

The WHO, in collaboration with the Bill and Melinda Gates Foundation and the International AIDS Society developed the Global HIV Drug Resistance Network. It is comprised of a network of countries and accredited laboratories. The Network serves as an advisory and evaluation function to the WHO HIV drug resistance team and countries implementing the strategy. Surveillance of HIV drug resistance is critical because it helps to detect the circulation of resistance strains and directs measures to preserve programme effectiveness.

This presentation will explore how lessons learnt from the HIV drug resistance initiative could be applied to slow the spread of MDR-GC.